Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review
/in Glioblastoma, Hyperthermia, International Publications /von 2021-03-13 / J Neurooncol 2021 May;152(3):419-428Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
/in Colorectal Cancer, Hyperthermia, International Publications /von 2021-03-13 / Cancers (Basel) 2021 Mar;13(6)Hyperthermia-Based Anti-Cancer Treatments
/in Hyperthermia, International Publications /von 2021-03-12 / Cancers (Basel) 2021 Mar;13(6)Neoadjuvant Hyperthermia and Chemoradiotherapy for Borderline Resectable Pancreatic Cancer
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2021-03-01 / Gan To Kagaku Ryoho 2021 Mar;48(3):388-390Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer
/in Colorectal Cancer, Hyperthermia, International Publications /von 2021-01-01 / Int J Hyperthermia 2021;38(1):144-151Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy
/in Hyperthermia, International Publications /von 2020-12-02 / Adv Mater 2021 Jan;33(4):e2004788Exhaustion of Protective Heat Shock Response Induces Significant Tumor Damage by Apoptosis after Modulated Electro-Hyperthermia Treatment of Triple Negative Breast Cancer Isografts in Mice
/in Breast Cancer, Hyperthermia, International Publications /von 2020-09-10 / Cancers (Basel) 2020 Sep;12(9)Quo Vadis Oncological Hyperthermia (2020)?
/in Hyperthermia, International Publications /von 2020-09-04 / Front Oncol 2020;10:1690
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
- Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
- Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma